MedTrace Logo

Study of a Peptide Cream's Effect on the Facial Skin Barrier Using a Side-by-Side Comparison

NCT07548424 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-06-17

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether a topical face cream containing the peptide Acetyl Hexapeptide-37 improves skin hydration and strengthens the skin barrier compared to a placebo cream in healthy adult participants. The study uses a split-face design, in which one side of the face is treated with the peptide cream and the other side with a placebo (a cream without the active ingredient).

The main questions it aims to answer are:

* Does the peptide cream improve skin hydration and reduce transepidermal water loss compared to placebo?
* Does the peptide cream affect skin erythema or cause irritation?
* How do participants rate the comfort and tolerability of the peptide cream?

Researchers will compare the treated and placebo sides of the face to assess differences in skin barrier function and tolerability.

Participants will:

* Attend a baseline visit for assessment of facial skin parameters, including hydration, transepidermal water loss, and erythema
* Apply the peptide cream to one side of the face and the placebo cream to the other side once daily for 4 weeks
* Attend weekly follow-up visits for non-invasive skin measurements
* Record any skin sensations (e.g., stinging, tightness) or adverse effects throughout the study

Conditions

  • Skin Barrier Function
  • Skin Hydration
  • Topical Peptide Effects on Facial Skin Barrier Function

Interventions

OTHER

Acetyl Hexapeptide-37 Cream

Topical emollient cream containing Acetyl Hexapeptide-37 as the active ingredient, applied once daily to one side of the face for 4 weeks.

OTHER

Placebo Cream

Topical emollient cream identical in composition to the investigational product but without Acetyl Hexapeptide-37, applied once daily to the contralateral side of the face for 4 weeks.

Sponsors & Collaborators

  • University of Split, School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-04
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07548424 on ClinicalTrials.gov